cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.29136805.v1
title: T-cell responses to highly conserved SARS-CoV-2 epitopes in Hispanic Americans receiving an mRNA COVID-19 vaccine

description: This study reports the pre-clinical evaluation of peptides from EPV-CoV-19, a T cell epitope-based SARS-CoV-2 vaccine candidate, following spike-mRNA vaccination of a predominantly Hispanic American cohort. EPV-COV-19 peptides’ potential to boost T cell responses to spike protein vaccines was evaluated, confirming previously observed memory recall responses in donors with prior immunity to COVID-19. The vaccinated subjects’ averaged immune responses to the 15-peptide EPV-CoV-19 pool achieved 85% of the observed response to a spike protein peptide array containing a 7-fold greater epitope content, suggesting that the EPV-CoV-19 peptides have a higher relative concentration of T cell epitope content per-peptide. Ten of the 15 peptides contained spike epitopes conserved in the majority of variants of concern (VOC) evaluated over the 2020–2024 period. While commercial vaccines exhibited gradual loss of T cell epitope conservation with VOC over time, the EPV-CoV-19 epitope-peptides maintained conservation until the XBB variant emerged. The addition of one new peptide to the vaccine design reestablished broad T cell epitope coverage. These findings underscore the importance of identifying highly conserved T cell epitopes for vaccine designs that target rapidly-mutating strains of emergent pathogens, while also documenting broad memory T cell response to the vaccine in a predominantly Hispanic American cohort.
DOI: 10.5281/zenodo.18711959
title: Lexical frequency data from DWDS corpora for a case study on regional variation in German

description: This dataset contains lexical frequency data from three DWDS corpora – the ZDL-Regionalkorpus, the Webmonitor-Korpus, and the Regionalliteratur-Korpus (not publicly accessible) – for a case study comparing the regional distribution of the following German nouns:



“Samstag” and “Sonnabend”,

“Komma” and “Beistrich”,

“Fahrrad”, “Radl”, and “Velo”,

“Aufzug”, “Fahrstuhl”, and “Lift”.


The dataset contains the following data types:



TXT files recording the corpus queries,

CSV tables with absolute and relative hit frequencies, obtained on 17 Feb. 2026 from the DWDS API,

SVG maps derived from the relative hit frequencies.
DOI: 10.6084/m9.figshare.29474366
title: Unleashing the power of the BCG vaccine in modulating viral immunity through heterologous protection: A scoping review

description: The Bacillus Calmette-Guérin (BCG) vaccine, used against tuberculosis for a century, shows promise in protecting against viral infections through trained/innate immunity. This review maps clinical and preclinical studies on both parental (WT) and recombinant BCG (rBCG) against 17 common viruses. From 68 studies, BCG strains were found to enhance innate immune responses by reprogramming myeloid cells, leading to stronger responses to related infections. Sixteen rBCG candidates expressed viral antigens, activating CD4+ and CD8+ T cells, and stimulating antibody production specific to the viral antigens. However, challenges like genetic stability and varied efficacy among BCG strains remain. The review highlights the potential of BCG, especially rBCG, as a multivalent vaccine platform for immunization campaigns, with significant public health implications. More translational studies and clinical trials are needed to confirm these findings.
DOI: 10.6084/m9.figshare.29474366.v1
title: Unleashing the power of the BCG vaccine in modulating viral immunity through heterologous protection: A scoping review

description: The Bacillus Calmette-Guérin (BCG) vaccine, used against tuberculosis for a century, shows promise in protecting against viral infections through trained/innate immunity. This review maps clinical and preclinical studies on both parental (WT) and recombinant BCG (rBCG) against 17 common viruses. From 68 studies, BCG strains were found to enhance innate immune responses by reprogramming myeloid cells, leading to stronger responses to related infections. Sixteen rBCG candidates expressed viral antigens, activating CD4+ and CD8+ T cells, and stimulating antibody production specific to the viral antigens. However, challenges like genetic stability and varied efficacy among BCG strains remain. The review highlights the potential of BCG, especially rBCG, as a multivalent vaccine platform for immunization campaigns, with significant public health implications. More translational studies and clinical trials are needed to confirm these findings.
DOI: 10.6084/m9.figshare.28623844
title: Meningococcal vaccination disparities in the United States (2010–2021): Findings from the National Immunization Survey-Teen and a commercial insurance database

description: In the United States, while meningococcal vaccines are available and recommended for adolescents and young adults, coverage remains low and disparities persist. We evaluated meningococcal serogroups A, C, W, Y (MenACWY) and B (MenB) vaccine uptake, completion, and compliance using a cross-sectional analysis of National Immunization Survey-Teen (NIS-Teen) data (2015–2021) and a cohort analysis of commercial claims data (2010–2021). Regression models were used to identify factors associated with vaccine uptake. Included in the NIS-Teen MenACWY and MenB analyses were 138,952 and 177,077 patients, respectively. Included in the claims MenACWY and MenB analyses were 953,905 and 818,424 patients, respectively. In 2021, MenACWY uptake was 86.4% (95% confidence interval [CI]: 83.6–88.8%) among ≤13-year-olds (NIS-Teen) and 63.2% (62.8–63.5%) among 11–12-year-olds (claims). MenB was 33.7% (30.5–37.1%) among ≤17-year-olds (NIS-Teen), 41.6% (41.2–42.0%) among 16–18-year-olds (claims), and 15.0% (14.7–15.4%) among 19–23-year-olds (claims). The states with the lowest and highest MenB uptake by ≤17-year-olds in 2021 (NIS-Teen) were Minnesota (10.1% [3.9–23.6%]) and North Dakota (69.9% [52.1–83.2%]). Factors associated with MenACWY uptake included living in a state with a vaccine mandate, Black or Hispanic race (versus White), and well-child visit attendance. Factors associated with MenB uptake included having Medicaid (versus private insurance) and Hispanic race (versus White). The findings suggest that meningococcal vaccination coverage disparities persist across vaccines, age, geography, and race and ethnicity. Higher MenACWY (versus MenB) coverage suggests the benefit of routine recommendations. Annual well-child visits and simplified vaccination schedules could reduce vaccination access barriers.
DOI: 10.6084/m9.figshare.28623844.v3
title: Meningococcal vaccination disparities in the United States (2010–2021): Findings from the National Immunization Survey-Teen and a commercial insurance database

description: In the United States, while meningococcal vaccines are available and recommended for adolescents and young adults, coverage remains low and disparities persist. We evaluated meningococcal serogroups A, C, W, Y (MenACWY) and B (MenB) vaccine uptake, completion, and compliance using a cross-sectional analysis of National Immunization Survey-Teen (NIS-Teen) data (2015–2021) and a cohort analysis of commercial claims data (2010–2021). Regression models were used to identify factors associated with vaccine uptake. Included in the NIS-Teen MenACWY and MenB analyses were 138,952 and 177,077 patients, respectively. Included in the claims MenACWY and MenB analyses were 953,905 and 818,424 patients, respectively. In 2021, MenACWY uptake was 86.4% (95% confidence interval [CI]: 83.6–88.8%) among ≤13-year-olds (NIS-Teen) and 63.2% (62.8–63.5%) among 11–12-year-olds (claims). MenB was 33.7% (30.5–37.1%) among ≤17-year-olds (NIS-Teen), 41.6% (41.2–42.0%) among 16–18-year-olds (claims), and 15.0% (14.7–15.4%) among 19–23-year-olds (claims). The states with the lowest and highest MenB uptake by ≤17-year-olds in 2021 (NIS-Teen) were Minnesota (10.1% [3.9–23.6%]) and North Dakota (69.9% [52.1–83.2%]). Factors associated with MenACWY uptake included living in a state with a vaccine mandate, Black or Hispanic race (versus White), and well-child visit attendance. Factors associated with MenB uptake included having Medicaid (versus private insurance) and Hispanic race (versus White). The findings suggest that meningococcal vaccination coverage disparities persist across vaccines, age, geography, and race and ethnicity. Higher MenACWY (versus MenB) coverage suggests the benefit of routine recommendations. Annual well-child visits and simplified vaccination schedules could reduce vaccination access barriers.
DOI: 10.6084/m9.figshare.30913505
title: MMRV vaccine safety: A comprehensive analysis of adverse events recorded among pediatric populations

description: Measles, mumps, rubella, and varicella (MMRV) vaccines are widely used in global immunization programs, but safety data on their administration in children remain limited. We analyzed adverse events following immunization(AEFIs) associated with the MMRV vaccine in children under seven y of age, as reported to the US Vaccine Adverse Event Reporting System (VAERS) from 2005 to 2025. Disproportionality analyses were applied, with multiple testing correction using a 5% false discovery rate. Subgroup assessments focused on children with asthma, epilepsy, and chronic kidney disease. The results show that among the 13,724 reports, 94.1% were non-serious cases, and the signal of Conjunctival Disorder had the highest reporting rate (ROR = 61.13, 95%confidence interval[CI]: 6.36-587.74). The risk of seizures in children with epilepsy significantly increased (ROR = 10.27, 95% CI: 6.57-16.05), with 63.2% occurring within 48 h after vaccination; a 6.81-fold increase in ROR was observed in the risk of wheezing in children with asthma, and no significant risk increment was observed in the chronic kidney disease group. Susceptibility to risks varied across subgroups. Weibull distribution analysis indicated that AEFIs following MMRV exhibited early-onset characteristics. This study provides a comprehensive understanding of MMRV vaccine safety and highlights the need for targeted protective measures in children with epilepsy and asthma to reduce vaccine hesitancy and improve vaccination coverage.
DOI: 10.6084/m9.figshare.30913505.v1
title: MMRV vaccine safety: A comprehensive analysis of adverse events recorded among pediatric populations

description: Measles, mumps, rubella, and varicella (MMRV) vaccines are widely used in global immunization programs, but safety data on their administration in children remain limited. We analyzed adverse events following immunization(AEFIs) associated with the MMRV vaccine in children under seven y of age, as reported to the US Vaccine Adverse Event Reporting System (VAERS) from 2005 to 2025. Disproportionality analyses were applied, with multiple testing correction using a 5% false discovery rate. Subgroup assessments focused on children with asthma, epilepsy, and chronic kidney disease. The results show that among the 13,724 reports, 94.1% were non-serious cases, and the signal of Conjunctival Disorder had the highest reporting rate (ROR = 61.13, 95%confidence interval[CI]: 6.36-587.74). The risk of seizures in children with epilepsy significantly increased (ROR = 10.27, 95% CI: 6.57-16.05), with 63.2% occurring within 48 h after vaccination; a 6.81-fold increase in ROR was observed in the risk of wheezing in children with asthma, and no significant risk increment was observed in the chronic kidney disease group. Susceptibility to risks varied across subgroups. Weibull distribution analysis indicated that AEFIs following MMRV exhibited early-onset characteristics. This study provides a comprehensive understanding of MMRV vaccine safety and highlights the need for targeted protective measures in children with epilepsy and asthma to reduce vaccine hesitancy and improve vaccination coverage.
DOI: 10.6084/m9.figshare.28623844.v2
title: Meningococcal vaccination disparities in the United States (2010–2021): Findings from the National Immunization Survey-Teen and a commercial insurance database

description: In the United States, while meningococcal vaccines are available and recommended for adolescents and young adults, coverage remains low and disparities persist. We evaluated meningococcal serogroups A, C, W, Y (MenACWY) and B (MenB) vaccine uptake, completion, and compliance using a cross-sectional analysis of National Immunization Survey-Teen (NIS-Teen) data (2015–2021) and a cohort analysis of commercial claims data (2010–2021). Regression models were used to identify factors associated with vaccine uptake. Included in the NIS-Teen MenACWY and MenB analyses were 138,952 and 177,077 patients, respectively. Included in the claims MenACWY and MenB analyses were 953,905 and 818,424 patients, respectively. In 2021, MenACWY uptake was 86.4% (95% confidence interval [CI]: 83.6–88.8%) among ≤13-year-olds (NIS-Teen) and 63.2% (62.8–63.5%) among 11–12-year-olds (claims). MenB was 33.7% (30.5–37.1%) among ≤17-year-olds (NIS-Teen), 41.6% (41.2–42.0%) among 16–18-year-olds (claims), and 15.0% (14.7–15.4%) among 19–23-year-olds (claims). The states with the lowest and highest MenB uptake by ≤17-year-olds in 2021 (NIS-Teen) were Minnesota (10.1% [3.9–23.6%]) and North Dakota (69.9% [52.1–83.2%]). Factors associated with MenACWY uptake included living in a state with a vaccine mandate, Black or Hispanic race (versus White), and well-child visit attendance. Factors associated with MenB uptake included having Medicaid (versus private insurance) and Hispanic race (versus White). The findings suggest that meningococcal vaccination coverage disparities persist across vaccines, age, geography, and race and ethnicity. Higher MenACWY (versus MenB) coverage suggests the benefit of routine recommendations. Annual well-child visits and simplified vaccination schedules could reduce vaccination access barriers.
DOI: 10.6084/m9.figshare.30294437
title: Longitudinal study on changes in COVID-19 vaccination intentions in Benin and Senegal: Insights from Generalized Estimating Equations (GEE)

description: The COVID-19 pandemic prompted strict measures and rapid vaccine deployment in Benin and Senegal. This longitudinal study uses Generalized Estimating Equations (GEE) to analyze the evolution of vaccination intent and its determinants, focusing on attitudes, risk perceptions, and social influence. This descriptive and analytical longitudinal study included 546 Beninese and 319 Senegalese individuals aged 18 and above, selected using marginal quotas. Data were collected via Random Digit Dialing (RDD) based on a questionnaire informed by the Theory of Planned Behavior (TPB) and the Health Belief Model (HBM). Influential factors were assessed using GEE models. Vaccination intent increased more significantly in Senegal (+12.5 points, <i>p</i> = .000) than in Benin (+5.0 points, <i>p</i> = .089). There was a statistically significant increase in vaccine intent among women (+19.9 points) and individuals under 25 (+15.6 points) in Senegal, whereas in Benin, younger respondents showed a decrease (−11.5 points). In both countries, individuals surveyed in the second phase were significantly more likely to express vaccination intent (Benin: OR = 6.9; Senegal: OR = 5.0). Common positive determinants included perceived benefits, social influence, and favorable attitudes toward vaccination. Differences emerged: perceived efficacy and behavioral control were significant in Benin, while safety concerns were a major barrier in Senegal. This study highlights common and context-specific determinants of vaccination intent in Benin and Senegal. It emphasizes the need for tailored communication strategies and efforts to strengthen public trust to enhance vaccine uptake across West Africa.
DOI: 10.6084/m9.figshare.30294437.v1
title: Longitudinal study on changes in COVID-19 vaccination intentions in Benin and Senegal: Insights from Generalized Estimating Equations (GEE)

description: The COVID-19 pandemic prompted strict measures and rapid vaccine deployment in Benin and Senegal. This longitudinal study uses Generalized Estimating Equations (GEE) to analyze the evolution of vaccination intent and its determinants, focusing on attitudes, risk perceptions, and social influence. This descriptive and analytical longitudinal study included 546 Beninese and 319 Senegalese individuals aged 18 and above, selected using marginal quotas. Data were collected via Random Digit Dialing (RDD) based on a questionnaire informed by the Theory of Planned Behavior (TPB) and the Health Belief Model (HBM). Influential factors were assessed using GEE models. Vaccination intent increased more significantly in Senegal (+12.5 points, <i>p</i> = .000) than in Benin (+5.0 points, <i>p</i> = .089). There was a statistically significant increase in vaccine intent among women (+19.9 points) and individuals under 25 (+15.6 points) in Senegal, whereas in Benin, younger respondents showed a decrease (−11.5 points). In both countries, individuals surveyed in the second phase were significantly more likely to express vaccination intent (Benin: OR = 6.9; Senegal: OR = 5.0). Common positive determinants included perceived benefits, social influence, and favorable attitudes toward vaccination. Differences emerged: perceived efficacy and behavioral control were significant in Benin, while safety concerns were a major barrier in Senegal. This study highlights common and context-specific determinants of vaccination intent in Benin and Senegal. It emphasizes the need for tailored communication strategies and efforts to strengthen public trust to enhance vaccine uptake across West Africa.
DOI: 10.6084/m9.figshare.28077389
title: Australian preferences for influenza vaccine attributes and cost: A discrete choice experiment

description: People in Australia have access to different influenza vaccines, but may be unaware of their options and features. Preference studies for differentiated influenza vaccines including cell-based vaccines are limited, particularly in Australia. This study investigated which influenza vaccine attributes people in Australia value using a discrete choice experiment (DCE). Adults in Australia ineligible for free influenza vaccines had been vaccinated in the last 5 years and intended to be vaccinated again completed an online survey. Participants (<i>N</i> = 1203) were presented three influenza vaccine profiles described by eight attributes. Half the DCE scenarios described influenza season severity to be the same as last year, and the other half as more severe. DCE data were analyzed using a mixed multinomial logit (MMNL) model. All eight attributes significantly predicted vaccine choice (<i>p</i> &lt; .05). Regardless of influenza season severity, participants preferred a vaccine: with greater protection, designed to be an exact match to circulating strains (match), using modern technology, manufactured by an Australian company, available at pharmacies, preferred by health care professionals (HCP), government funded for high-risk individuals and having lower cost. The top three attributes by importance were protection, match and cost. Participants were willing to pay more for match and higher protection. The Marginal Willingness to Pay (MWTP) for the most important attributes, excluding cost, were AUD $1.61/$2.18 for each additional percent in protection (same/more severe season), AUD $25.37/$32.37 for match and AUD $4.06/$15.97 for HCP preference. Findings indicate that match, protection, cost and HCP preference are key to vaccine choice, highlighting the importance of shared decision-making.
DOI: 10.6084/m9.figshare.28077389.v1
title: Australian preferences for influenza vaccine attributes and cost: A discrete choice experiment

description: People in Australia have access to different influenza vaccines, but may be unaware of their options and features. Preference studies for differentiated influenza vaccines including cell-based vaccines are limited, particularly in Australia. This study investigated which influenza vaccine attributes people in Australia value using a discrete choice experiment (DCE). Adults in Australia ineligible for free influenza vaccines had been vaccinated in the last 5 years and intended to be vaccinated again completed an online survey. Participants (<i>N</i> = 1203) were presented three influenza vaccine profiles described by eight attributes. Half the DCE scenarios described influenza season severity to be the same as last year, and the other half as more severe. DCE data were analyzed using a mixed multinomial logit (MMNL) model. All eight attributes significantly predicted vaccine choice (<i>p</i> &lt; .05). Regardless of influenza season severity, participants preferred a vaccine: with greater protection, designed to be an exact match to circulating strains (match), using modern technology, manufactured by an Australian company, available at pharmacies, preferred by health care professionals (HCP), government funded for high-risk individuals and having lower cost. The top three attributes by importance were protection, match and cost. Participants were willing to pay more for match and higher protection. The Marginal Willingness to Pay (MWTP) for the most important attributes, excluding cost, were AUD $1.61/$2.18 for each additional percent in protection (same/more severe season), AUD $25.37/$32.37 for match and AUD $4.06/$15.97 for HCP preference. Findings indicate that match, protection, cost and HCP preference are key to vaccine choice, highlighting the importance of shared decision-making.
DOI: 10.6084/m9.figshare.30553033
title: Determinants of non-compliance with additional booster doses of the SARS-CoV-2 vaccine in people living with HIV (PWH): An observational study based on a behavioral and epidemiological survey in Rome (Italy)

description: Rejection of new anti-SARS-CoV-2 booster doses among immunosuppressed and elderly individuals may be a concern, especially as the intention to vaccinate does not always translate into actual behavior. Few studies have addressed this issue in people living with HIV (PWH). We investigated attitudes of PWH toward SARS-CoV-2 vaccination, focusing on factors associated with noncompliance with additional vaccine doses (AVDs, 4th and 5th). We analyzed participants of the prospective observational HIV-VAC study conducted at the National Institute for Infectious Diseases “L. Spallanzani” IRCCS, Rome (September 2022–June 2023). Eligible patients with complete vaccination schedules were voluntarily recruited and completed a 13-item survey on demographics and vaccination attitudes. Multivariate logistic regression was used to describe the relationship between “compliant” vs. “non-compliant” groups. Of 316 participants, 240 (75.9%) were compliant and 76 (24.1%) non-compliant. Compliance was 70% for the fourth and 30% for the fifth dose; noncompliance was 19.9% and 4.1%, respectively. Older age (<i>p</i> = .012) and information from non-institutional sources (<i>p </i>&lt; .0001) were associated with higher noncompliance. Among non-compliant participants, 34.4% reported concerns about side effects. In PWH aged &gt;50, fear of side effects and reliance on unofficial information sources are major barriers to AVD uptake. Non-compliant individuals tend to persist in their refusal over time. Tailored communication and healthcare professional training are crucial to improve vaccine adherence, and further multicenter studies are warranted.